Ocular Therapeutix (OCUL) Prepares New AXPAXLI Data, Is The Stock Still Below Fair Value?
Conference spotlight puts Ocular Therapeutix stock back in focus
Ocular Therapeutix (OCUL) is drawing fresh attention as it prepares to share Phase 3 SOL-1 Superiority Trial data for AXPAXLI at major investor and scientific conferences in the coming weeks.
This cluster of presentations, including the 19th Asia-Pacific Vitreo-retina Society Congress on August 29, 2026, offers a clearer view of the company’s progress in retinal disease research and how the story around its stock is evolving.
Against this backdrop of data-rich conferences, Ocular Therapeutix has seen a 29.9% 1 month share price return and a 24.0% 3 month share price return. However, the share price is still down 7.7% year to date, while the 3 year total shareholder return is very large at about 3x, suggesting recent momentum has picked up after a weaker patch.
Compare Ocular Therapeutix’s conference-fueled momentum with other under-the-radar growth stories by scanning our hand picked list of 20 high quality undiscovered gems.
Bulls point to Ocular Therapeutix’s conference momentum and revenue growth, while bears highlight ongoing losses and weaker recent shareholder returns. Which side does the current valuation lean toward as the stock resets around US$10.91?
Most Popular Narrative: 59.7% Undervalued
Ocular Therapeutix is trading at $10.91 compared with a widely followed fair value narrative of $27.09, which puts a spotlight on what is driving that gap.
The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.
Want to understand why this narrative points to such a large upside gap for Ocular Therapeutix? The story leans heavily on rapid revenue expansion, a sharp swing in margins, and a premium future earnings multiple that assumes Axpaxli scales far beyond today’s financial base.
Result: Fair Value of $27.09 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Ocular Therapeutix still leans heavily on AXPAXLI success. Any trial or regulatory setback, along with higher than expected R&D spending, could quickly challenge this upside story.
Find out about the key risks to this Ocular Therapeutix narrative.
Another View on Ocular Therapeutix valuation
The SWS DCF model paints a very different picture for Ocular Therapeutix. At a share price of $10.91, it suggests the stock trades well below an estimated future cash flow value of $112.16. That is a deep discount on paper, but does it simply magnify the same Axpaxli assumptions you saw in the narrative-based fair value?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Given the mix of optimism and concern in this Ocular Therapeutix story, consider acting promptly, reviewing the underlying numbers, and deciding where you stand after weighing the 2 key rewards and 3 important warning signs.
Looking for more Ocular Therapeutix investment ideas?
If Ocular Therapeutix has caught your attention, do not stop here. Use the Simply Wall Street Screener to hunt for stocks that better match your goals.
- Spot potential bargains by scanning companies that combine quality fundamentals with attractive prices using the 54 high quality undervalued stocks.
- Build resilience into your portfolio by reviewing a list of solid balance sheet and fundamentals (52 results) that can better handle challenging conditions.
- Reduce potential shocks by checking a group of 73 resilient stocks with low risk scores that may offer a smoother ride.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com